

MAINSTREAMING ADDICTION TREATMENT ACT (H.R. 1384 / S. 445)

SUMMARY OF SOLUTIONS INCLUDED IN THE FY 2023 OMNIBUS

CURRENT FEDERAL RULES

Health care providers must **apply for an "X-Waiver"** from SAMSHA and the DEA before prescribing buprenorphine for opioid use disorder.

Health care providers must adhere to **strict limits on the number of patients** with opioid use disorder that they can treat at a time.

Health care providers must **mark buprenorphine prescriptions for patients with opioid use disorder with an "X"** using a special DEA number.

Health care providers must attest to their **ability to refer patients to counseling and ancillary services** before prescribing buprenorphine for opioid use disorder to more than 30 patients at a time.

Health care providers must engage in an **8-24-hour X-Waiver training** before prescribing buprenorphine for opioid use disorder to more than 30 patients at a time.

Only certain **eligible health care providers (e.g., physicians, advanced practice registered nurses, physician assistants)** can prescribe buprenorphine for opioid use disorder.

MAT ACT CHANGES INCLUDED IN THE OMNIBUS

Removes the X-Waiver registration requirement. All health care providers with a standard DEA controlled medication license will be able to prescribe buprenorphine for opioid use disorder without separate registration, subject to state requirements.

Removes the patient limits. All health care providers with a standard DEA controlled medication license will be able to prescribe buprenorphine for opioid use disorder to as many patients in their practice as needed, subject to state requirements.

Removes the special DEA "X" prescribing number. Health care providers can use their standard DEA controlled substance license number to prescribe buprenorphine for opioid use disorder.

Removes counseling referral and ancillary services requirement. Health care providers with a standard DEA controlled medication license can prescribe buprenorphine for opioid use disorder in the course of their normal medical practices, subject to state requirements.

Removes X-Waiver training requirement. Health care providers with a standard DEA controlled medication license can prescribe buprenorphine for opioid use disorder, subject to state requirements. A separate section of the omnibus will require that all health care providers registered with the DEA take an 8-hour course on substance use disorder. But the completion of this course is not required before starting to prescribe buprenorphine.

Removes list of health care providers who can prescribe buprenorphine for opioid use disorder. Any health care provider with a standard DEA controlled medication license can prescribe buprenorphine, subject to state requirements.

For more information, please contact us at erin@endsud.org
www.endsud.org/mat-act

END
SUBSTANCE
USE DISORDER